BACKGROUND Experimental studies have reported nonsteroidal anti-inflammatory drugs (NSAIDs) could impair tendon healing. The purpose of this study was to investigate whether NSAIDs could affect recovery of knee joint function in patients after anterior cruciate ligament (ACL) reconstruction. MATERIAL AND METHODS We enrolled 40 patients treated with celecoxib and 40 patients treated with tramadol, who underwent ACL reconstruction from January 2011 to December 2017. Visual analogue scale (VAS) and functional outcomes were collected and evaluated. The follow-up period was 12 months. RESULTS In both groups, all patients obtained pain release after surgery, compared with that before surgery. But no significant differences were observed between the 2 groups in VAS scores. We also did not find any differences between the 2 groups at 1 year of follow-up, in terms of anterior drawer test, Lachman test, side-to-side laxity assessed by KT-2000, IKDC score, Lysholm score, and Tegner scale. However, the celecoxib group showed a reduced incidence of nausea compared to the tramadol group (P=0.048). CONCLUSIONS The use of NSAIDs after ACL reconstruction is relatively safe and could decrease adverse side effects which were caused by opioid drugs.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6128182PMC
http://dx.doi.org/10.12659/MSM.910942DOI Listing

Publication Analysis

Top Keywords

acl reconstruction
12
nonsteroidal anti-inflammatory
8
anti-inflammatory drugs
8
anterior cruciate
8
cruciate ligament
8
patients treated
8
drugs affect
4
affect tissue
4
tissue healing
4
healing arthroscopic
4

Similar Publications

Kember, LS, Riehm, CD, Schille, A, Slaton, JA, Myer, GD, and Lloyd, RS. Residual biomechanical deficits identified with the tuck jump assessment in female athletes 9 months after ACLR surgery. J Strength Cond Res 38(12): 2065-2073, 2024-Addressing biomechanical deficits in female athletes after anterior cruciate ligament reconstruction (ACLR) is crucial for safe return-to-play.

View Article and Find Full Text PDF

Objective: The objective of this systematic review and meta-analysis is to clarify the rehabilitation efficacy of virtual reality (VR) balance training after anterior cruciate ligament reconstruction (ACLR).

Methods: This meta-analysis was registered in PROSPERO with the registration number CRD42024520383. The electronic databases PubMed, Web of Science, Cochrane Library, MEDLINE, Embase, China National Knowledge Infrastructure, Chinese Biomedical Literature, China Science and Technology Journal Database, and Wanfang Digital Periodical database were systematically searched to identify eligible studies from their inception up to January 2024.

View Article and Find Full Text PDF

Kember, LS, Riehm, CD, Schille, A, Slaton, JA, Myer, GD, and Lloyd, RS. Residual biomechanical deficits identified with the tuck jump assessment in female athletes 9 months after ACLR surgery. J Strength Cond Res XX(X): 000-000, 2024-Addressing biomechanical deficits in female athletes after anterior cruciate ligament reconstruction (ACLR) is crucial for safe return-to-play.

View Article and Find Full Text PDF

Injury of the anterior cruciate ligament (ACL) in the knee is common, with up to 250,000 cases annually in the United States. Such injuries can lead to muscle atrophy, impaired balance, and limited movement. This study aimed to compare the lower limbs of individuals with ACL reconstruction to a Control group.

View Article and Find Full Text PDF

Background: The failure rate of anterior cruciate ligament (ACL) reconstruction in children and adolescents is a significant concern. Of the multitude of clinical factors that contribute to this risk, delayed maturation and graft laxity are potentially related and modifiable elements. The aim was to investigate knee anterior laxity and graft maturation in children and adolescents.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!